[Tiaoshen Guben holistic therapy of acupuncture and moxibustion for 24 cases of comorbidity of depression and insomnia].

Researchers in China studied a comprehensive acupuncture and moxibustion treatment approach for 24 patients suffering from both depression and insomnia together. The therapy, called "Tiaoshen Guben holistic therapy," combined three techniques: traditional acupuncture at points including Baihui (top of head), Guanyuan (lower abdomen), and Neiguan (inner forearm); refined moxibustion (heat therapy) at Zhongwan, Qihai, and Yongquan points; and subcutaneous embedding therapy using small thumb-tack needles at Xinshu and Pishu points on the back. Patients received treatment three times weekly for six weeks.

The results showed significant improvements in both sleep quality and depression symptoms that lasted at least one month after treatment ended. Using brain imaging technology, researchers discovered that the treatment strengthened connections between specific brain regions involved in mood and sleep regulation. Blood tests revealed favorable changes in stress hormones: cortisol, ACTH, and CRH all decreased, while norepinephrine (which helps regulate alertness and mood) increased.

The brain connectivity improvements correlated with better sleep scores and reduced depression, suggesting the treatment works through measurable biological mechanisms rather than placebo effect alone. This integrated approach combining multiple acupuncture techniques appears promising for people struggling with the common combination of depression and insomnia, conditions that often reinforce each other and prove difficult to treat. If you're considering acupuncture for depression or sleep issues, seek a licensed acupuncturist with experience treating mental health conditions.

This uncontrolled clinical study (n=24) evaluated a comprehensive acupuncture protocol for comorbid depression and insomnia over 6 weeks (3 sessions/week). The intervention combined manual acupuncture (Baihui GV20, Guanyuan CV4, bilateral Neiguan PC6), refined moxibustion (Zhongwan CV12, Qihai CV6, bilateral Yongquan KI1), and subcutaneous thumbtack needle embedding (bilateral Xinshu BL15, Pishu BL20). Results showed statistically significant reductions in PSQI and HAMD-17 scores post-treatment and at 1-month follow-up (P<0.01). fMRI analysis revealed strengthened functional connectivity between right locus coeruleus and left inferior frontal gyrus pars opercularis, with connectivity changes negatively correlating with symptom improvements (r=-0.484 for PSQI, r=-0.233 for HAMD-17). Serum biomarkers showed increased norepinephrine and decreased cortisol, ACTH, and CRH (P<0.01). The multimodal approach demonstrates promise for this patient population, though controlled trials are needed to establish causality and optimal treatment parameters.